Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rohto Pharmaceutical Co.,Ltd. (4527.T)
JPY2,483.00
-8.50 (-0.34%)
JP JPX Consumer Defensive Household & Personal Products
Address
1-8-1, Tatsumi-nishi 544-8666
Osaka, JP
Osaka, JP
CEO
Hidetoshi Segi
Website
rohto.co.jp
IPO
2001-01-04
ISIN JP3982400008
Also trades on
Other OTC · RPHCF (USD)
Tokyo Stock Exchange · 4527.T (JPY)
Description
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY2,483.00
-8.50 (-0.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
834.7K
Beta
-0.46
Float Shares
200.75M
Free Float %
88.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.19% | +2.35% | -0.04% | -4.02% | -1.11% | -8.04% | +10.76% | -20.10% | +73.22% | +191.95% | +571.68% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,483.00
DCF (Unlevered)
6,763.43
+172.4%
DCF (Levered)
10,644.63
+328.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
64% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 4 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.03
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Household & Personal Products: +3.3%+11.4% ★ Q1'26: +9.6% (vs Q1'25)
-
EPS growth Household & Personal Products: +8.8%+7.3% Q1'26: -10.5% (vs Q1'25)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+7.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Household & Personal Products: +9.9%+11.8% ★ Q1'26: +8.2% (vs Q1'25)
-
ROIC Household & Personal Products: +8.2%+10.2% ★ Q1'26: +7.7% (vs Q1'25)
-
Share dilution Household & Personal Products: +0.2%+2.9% Q1'26: +7.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×1.04× Q1'26: 1.24× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 11 Rev. Ana. 10 EPS Ana. |
Mar 2027 7 Rev. Ana. 6 EPS Ana. |
Mar 2028 9 Rev. Ana. 9 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
151.77B
est: 151.53B (+0.2%)
|
167.02B
est: 168.75B (-1.0%)
|
154.60B
est: 153.65B (+0.6%)
|
171.80B
est: 167.73B (+2.4%)
|
183.67B
est: 183.65B (+0.0%)
|
188.38B
est: 187.02B (+0.7%)
|
181.05B
est: 181.24B (-0.1%)
|
199.65B
est: 195.18B (+2.3%)
|
238.66B
est: 231.78B (+3.0%)
|
270.84B
est: 278.03B (-2.6%)
|
308.63B
est: 312.05B (-1.1%)
|
338.92B
324.20B – 343.30B
+8.6% YoY
|
358.05B
352.48B – 366.63B
+5.6% YoY
|
374.34B
363.25B – 391.89B
+4.5% YoY
|
400.20B
398.80B – 401.60B
+6.9% YoY
|
412.15B
402.79B – 426.84B
+3.0% YoY
|
| EBITDA |
19.50B
est: 26.78B (-27.2%)
|
22.13B
est: 29.83B (-25.8%)
|
21.38B
est: 27.16B (-21.3%)
|
24.67B
est: 29.65B (-16.8%)
|
26.96B
est: 32.46B (-17.0%)
|
29.82B
est: 33.05B (-9.8%)
|
28.62B
est: 32.03B (-10.7%)
|
35.55B
est: 34.50B (+3.0%)
|
41.34B
est: 40.97B (+0.9%)
|
48.85B
est: 47.65B (+2.5%)
|
51.61B
est: 53.48B (-3.5%)
|
58.09B
55.56B – 58.84B
+8.6% YoY
|
61.36B
60.41B – 62.83B
+5.6% YoY
|
64.15B
62.26B – 67.16B
+4.5% YoY
|
68.59B
68.35B – 68.83B
+6.9% YoY
|
70.63B
69.03B – 73.15B
+3.0% YoY
|
| EBIT |
13.16B
est: 21.23B (-38.0%)
|
15.68B
est: 23.65B (-33.7%)
|
15.45B
est: 21.53B (-28.2%)
|
18.76B
est: 23.50B (-20.2%)
|
20.55B
est: 25.73B (-20.1%)
|
22.88B
est: 26.21B (-12.7%)
|
21.87B
est: 25.40B (-13.9%)
|
27.86B
est: 27.35B (+1.9%)
|
33.54B
est: 32.48B (+3.3%)
|
40.17B
est: 37.47B (+7.2%)
|
38.47B
est: 42.05B (-8.5%)
|
45.67B
43.69B – 46.26B
+8.6% YoY
|
48.25B
47.50B – 49.41B
+5.6% YoY
|
50.44B
48.95B – 52.81B
+4.5% YoY
|
53.93B
53.74B – 54.12B
+6.9% YoY
|
55.54B
54.28B – 57.52B
+3.0% YoY
|
| Net Income |
8.63B
est: 8.91B (-3.1%)
|
9.10B
est: 9.97B (-8.8%)
|
10.01B
est: 8.78B (+14.0%)
|
9.29B
est: 11.81B (-21.4%)
|
9.80B
est: 13.58B (-27.8%)
|
15.41B
est: 13.97B (+10.3%)
|
16.74B
est: 14.05B (+19.1%)
|
21.13B
est: 19.99B (+5.7%)
|
26.38B
est: 23.98B (+10.0%)
|
30.94B
est: 30.33B (+2.0%)
|
31.01B
est: 31.71B (-2.2%)
|
33.13B
31.60B – 34.19B
+4.5% YoY
|
34.90B
32.92B – 35.46B
+5.3% YoY
|
35.32B
34.35B – 39.74B
+1.2% YoY
|
37.00B
36.91B – 40.68B
+4.8% YoY
|
40.87B
39.66B – 42.76B
+10.5% YoY
|
| SGA |
70.55B
est: 58.55B (+20.5%)
|
76.24B
est: 65.21B (+16.9%)
|
68.41B
est: 59.37B (+15.2%)
|
74.44B
est: 64.81B (+14.8%)
|
80.86B
est: 70.97B (+13.9%)
|
82.73B
est: 72.27B (+14.5%)
|
75.15B
est: 70.03B (+7.3%)
|
77.46B
est: 75.42B (+2.7%)
|
90.48B
est: 89.56B (+1.0%)
|
101.31B
est: 107.43B (-5.7%)
|
116.00B
est: 120.58B (-3.8%)
|
130.96B
125.28B – 132.66B
+8.6% YoY
|
138.36B
136.20B – 141.67B
+5.6% YoY
|
144.65B
140.37B – 151.43B
+4.5% YoY
|
154.64B
154.10B – 155.18B
+6.9% YoY
|
159.26B
155.64B – 164.94B
+3.0% YoY
|
| EPS |
38.03
est: 38.90 (-2.2%)
|
40.02
est: 43.56 (-8.1%)
|
43.97
est: 38.37 (+14.6%)
|
40.77
est: 51.61 (-21.0%)
|
43.00
est: 59.33 (-27.5%)
|
67.56
est: 61.02 (+10.7%)
|
73.39
est: 61.40 (+19.5%)
|
92.61
est: 87.31 (+6.1%)
|
115.62
est: 105.21 (+9.9%)
|
135.60
est: 132.94 (+2.0%)
|
136.11
est: 137.39 (-0.9%)
|
146.12
138.07 – 149.37
+6.4% YoY
|
148.58
143.83 – 154.91
+1.7% YoY
|
157.59
150.09 – 173.59
+6.1% YoY
|
169.50
161.27 – 177.74
+7.6% YoY
|
178.55
173.28 – 186.82
+5.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
10.60B
OE per share TTM
46.30
Owner's Yield
1.94%
Maintenance CapEx ratio
32.02%
Maint CapEx / Avg PPE
27.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 111 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pan Asia Dividend Aristocrats UCITS ETF (Dist) ASDV.L | 0.29% | 703.8K | 0.55% |
| 2 | iShares MSCI Japan Small-Cap ETF SCJ | 0.21% | 538.5K | 0.50% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.20% | 1.15M | 0.58% |
| 4 | Amundi S&P World Consumer Staples Screened UCITS ETF Acc STAW.MI | 0.08% | 243.0K | 0.18% |
| 5 | Schwab Fundamental International Small Company Index ETF FNDC | 0.08% | 2.38M | 0.39% |
| 6 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.08% | 174.5K | 0.83% |
| 7 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.08% | 10.51M | 0.40% |
| 8 | Invesco JPX-Nikkei 400 UCITS ETF N4US.L | 0.07% | 135.1K | 0.19% |
| 9 | Invesco JPX-Nikkei 400 UCITS ETF NS4E.DE | 0.07% | 134.7K | 0.19% |
| 10 | Invesco JPX-Nikkei 400 UCITS ETF N400.L | 0.07% | 134.8K | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
5.61M
Shares Outstanding
225.96M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideto Kamimura | Senior Executive Officer and General Manager of Marketing Division | — | male |
| Hidetoshi Segi | Chief Operating Officer, President & Representative Director | — | male |
| Masae Yamanaka | Chief Transformation Officer & Director | — | female |
| Noriko Suenobe | Chief Research Officer & Director | — | female |
| Saito Masaya | Executive Vice President, Chief Financial Officer & Director | — | male |
| Shinichi Kunisaki | Executive Vice President, Chief Technology Officer & Director | — | male |
| Yasunori Kawasaki | Chief Human Resources Officer & Director | — | male |
| Yoichi Honma | Chief Scientific Officer & Director | — | male |
| Yoko Fujimoto | MD, Chief Medical Officer & Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4527.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
